Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.

MLA

Gore, Steven D., et al. “Single Cycle of Arsenic Trioxide-Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 28, no. 6, Feb. 2010, pp. 1047–53. EBSCOhost, https://doi.org/10.1200/JCO.2009.25.5158.

APA

Gore, S. D., Gojo, I., Sekeres, M. A., Morris, L., Devetten, M., Jamieson, K., Redner, R. L., Arceci, R., Owoeye, I., Dauses, T., Schachter-Tokarz, E., & Gallagher, R. E. (2010). Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 28(6), 1047–1053. https://doi.org/10.1200/JCO.2009.25.5158

Chicago

Gore, Steven D, Ivana Gojo, Mikkael A Sekeres, Lawrence Morris, Marcel Devetten, Katarzyna Jamieson, Robert L Redner, et al. 2010. “Single Cycle of Arsenic Trioxide-Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28 (6): 1047–53. doi:10.1200/JCO.2009.25.5158.